APGE logo

Apogee Therapeutics (APGE) Cash From Financing

Annual CFF

$495.11 M
+$179.72 M+56.98%

December 31, 2024


Summary


Performance

APGE Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherAPGEcash flowmetrics:

Quarterly CFF

$44.36 M
+$43.97 M+11481.20%

December 31, 2024


Summary


Performance

APGE Quarterly CFF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherAPGEcash flowmetrics:

TTM CFF

$495.11 M
+$44.57 M+9.89%

December 31, 2024


Summary


Performance

APGE TTM CFF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherAPGEcash flowmetrics:

Cash From Financing Formula

CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities

APGE Cash From Financing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+57.0%+10000.0%-35.5%
3 y3 years+194.2%+2718.4%+10000.0%
5 y5 years+194.2%+2718.4%+10000.0%

APGE Cash From Financing Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+194.2%-90.2%+2718.4%-35.5%>+9999.0%
5 y5-yearat high+194.2%-90.2%+2718.4%-35.5%>+9999.0%
alltimeall timeat high+194.2%-90.2%+2718.4%-35.5%>+9999.0%

Apogee Therapeutics Cash From Financing History

DateAnnualQuarterlyTTM
Dec 2024
$495.11 M(+57.0%)
$44.36 M(>+9900.0%)
$495.11 M(+9.9%)
Sep 2024
-
$383.00 K(-355.3%)
$450.54 M(-41.3%)
Jun 2024
-
-$150.00 K(-100.0%)
$767.46 M(+0.2%)
Mar 2024
-
$450.52 M(<-9900.0%)
$765.91 M(+142.8%)
DateAnnualQuarterlyTTM
Dec 2023
$315.39 M(+87.4%)
-$213.00 K(-100.1%)
$315.39 M(-0.1%)
Sep 2023
-
$317.30 M(<-9900.0%)
$315.60 M(<-9900.0%)
Jun 2023
-
-$1.69 M(<-9900.0%)
-$1.69 M(<-9900.0%)
Mar 2023
-
$0.00
$0.00
Dec 2022
$168.32 M
-
-

FAQ

  • What is Apogee Therapeutics annual cash flow from financing activities?
  • What is the all time high annual CFF for Apogee Therapeutics?
  • What is Apogee Therapeutics annual CFF year-on-year change?
  • What is Apogee Therapeutics quarterly cash flow from financing activities?
  • What is the all time high quarterly CFF for Apogee Therapeutics?
  • What is Apogee Therapeutics quarterly CFF year-on-year change?
  • What is Apogee Therapeutics TTM cash flow from financing activities?
  • What is the all time high TTM CFF for Apogee Therapeutics?
  • What is Apogee Therapeutics TTM CFF year-on-year change?

What is Apogee Therapeutics annual cash flow from financing activities?

The current annual CFF of APGE is $495.11 M

What is the all time high annual CFF for Apogee Therapeutics?

Apogee Therapeutics all-time high annual cash flow from financing activities is $495.11 M

What is Apogee Therapeutics annual CFF year-on-year change?

Over the past year, APGE annual cash flow from financing activities has changed by +$179.72 M (+56.98%)

What is Apogee Therapeutics quarterly cash flow from financing activities?

The current quarterly CFF of APGE is $44.36 M

What is the all time high quarterly CFF for Apogee Therapeutics?

Apogee Therapeutics all-time high quarterly cash flow from financing activities is $450.52 M

What is Apogee Therapeutics quarterly CFF year-on-year change?

Over the past year, APGE quarterly cash flow from financing activities has changed by +$44.51 M (+29670.67%)

What is Apogee Therapeutics TTM cash flow from financing activities?

The current TTM CFF of APGE is $495.11 M

What is the all time high TTM CFF for Apogee Therapeutics?

Apogee Therapeutics all-time high TTM cash flow from financing activities is $767.46 M

What is Apogee Therapeutics TTM CFF year-on-year change?

Over the past year, APGE TTM cash flow from financing activities has changed by -$272.35 M (-35.49%)